Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$120.02 USD

120.02
6,084,271

-0.45 (-0.37%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $120.06 +0.04 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (141 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers

by Zacks Equity Research

Intercept (ICPT) gains on a better-than-expected second quarter as loss narrows and sales surpass estimates on a significant recovery in Ocaliva.

    Zacks Equity Research

    Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM

    by Zacks Equity Research

    Zacks.com featured highlights include: Biogen, Thermo Fisher, HCA, Gilead and QUALCOMM

      Zacks Equity Research

      Zoetis (ZTS) Beats on Q2 Earnings & Sales, Updates '18 View

      by Zacks Equity Research

      Zoetis second-quarter 2018 results exceed both earnings and sales estimates. The company completes the acquisition of Abaxis, Inc.

        Zacks Equity Research

        5 Cheap PEG Stocks Suitable for GARP Investors

        by Zacks Equity Research

        Although PEG is categorized under value investing, this strategy follows the principles of both growth and value investing.

          Zacks Equity Research

          Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2

          by Zacks Equity Research

          During the second quarter of 2018, the boards of Takeda and Shire (SHPG) reached an agreement pursuant to which the former will acquire the entire issued and to-be-issued ordinary share capital of the latter.

            Zacks Equity Research

            Endocyte (ECYT) Posts Narrower-Than-Expected Loss in Q2

            by Zacks Equity Research

            Endocyte (ECYT) initiates a phase III VISION study for its lead pipeline candidate,-177Lu-PSMA-617, during the second quarter of 2018.

              Zacks Equity Research

              Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit

              by Zacks Equity Research

              Impressive second-quarter results by most biotech bigwigs were the key highlights of the week. Most companies upped their guidance.

                Zacks Equity Research

                Sanofi's (SNY) Q2 Earnings Surpass Estimates, Sales Miss

                by Zacks Equity Research

                Sanofi (SNY) beats earnings but misses on sales in the second quarter of 2018 owing to currency headwinds and struggling diabetes and cardiovascular unit.

                  Zacks Equity Research

                  Is Gilead Sciences (GILD) Outperforming Other Medical Stocks This Year?

                  by Zacks Equity Research

                  Is (GILD) Outperforming Other Medical Stocks This Year?

                    Zacks Equity Research

                    Allergan (AGN) Beats on Q2 Earnings, Unveils Buyback Plan

                    by Zacks Equity Research

                    Allergan (AGN) beats second-quarter estimates for earnings and sales and raises its full-year outlook for both the metrics. The board authorizes a new $2.0 billion share buyback plan.

                      Zacks Equity Research

                      AstraZeneca's (AZN) Q2 Earnings and Sales Beat, Stock Up

                      by Zacks Equity Research

                      AstraZeneca (AZN) beats earnings and sales estimates in the second quarter on the back of strong new product sales and maintains previously issued outlook for 2018.

                        Zacks Equity Research

                        Alexion's (ALXN) Earnings Beat Estimates in Q2, Guidance Up

                        by Zacks Equity Research

                        ALexion (ALXN) beats both earnings and revenue estimates in the second quarter of 2018, and completes the acquisition of Wilson Therapeutics.

                          Zacks Equity Research

                          Microsoft, H&R Block, Facebook, Qualcomm and Gilead highlighted as Zacks Bull and Bear of the Day

                          by Zacks Equity Research

                          Microsoft, H&R Block, Facebook, Qualcomm and Gilead highlighted as Zacks Bull and Bear of the Day

                            Zacks Equity Research

                            Gilead (GILD) Q2 Earnings & Sales Beat Eclipsed by CEO Exit

                            by Zacks Equity Research

                            Gilead's GILD) stock is down in after-market trading as the news of departure of the company's CEO has overshadowed the company's second-quarter results, which beat estimates.

                              Mark Vickery headshot

                              Facebook Misses 1st Time in 11 Quarters; Plus GILD, QCOM

                              by Mark Vickery

                              Facebook has posted a one-penny miss, but revenues also came in lower than expected.

                                Zacks Equity Research

                                Gilead Sciences (GILD) Q2 Earnings and Revenues Surpass Estimates

                                by Zacks Equity Research

                                Gilead (GILD) delivered earnings and revenue surprises of 23.23% and 9.08%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

                                  Zacks Equity Research

                                  Biotech Stock Roundup: Biogen Gains on Q2 Results, Agios Gets FDA Nod For Leukemia Drug

                                  by Zacks Equity Research

                                  The biotech sector is in focus as bigwig Biogen gains on better-than-expected Q2 results. Others like Gilead, Amgen and Celgene too are slated to report shortly.

                                    Zacks Equity Research

                                    Is a Beat in the Cards for AbbVie (ABBV) in Q2 Earnings?

                                    by Zacks Equity Research

                                    Impressive sales of AbbVie's (ABBV) key drugs, Humira, Imbruvica and Mavyret, might lead the company to an earnings beat in the second quarter.

                                      Zacks Equity Research

                                      Is a Beat in Store for Keryx (KERX) This Earnings Season?

                                      by Zacks Equity Research

                                      Keryx (KERX) is likely to provide updates on the merger with Akebia along with the updates on Auryxia at the second quarter call.

                                        Zacks Equity Research

                                        Pharma/Biotech Stock Q2 Earnings on Jul 25: GILD, VRTX & GSK

                                        by Zacks Equity Research

                                        The going has been good for the pharma giants, which reported second-quarter results so far. Let us see what is in store for biotech bigwig GILD, VRTX and large-cap pharma company GSK.

                                          Zacks Equity Research

                                          Implied Volatility Surging for Gilead Sciences (GILD) Stock Options

                                          by Zacks Equity Research

                                          Investors need to pay close attention to Gilead Sciences (GILD) stock based on the movements in the options market lately.

                                            Zacks Equity Research

                                            Will Strong HIV Sales Fuel Gilead (GILD) In Q2 Earnings?

                                            by Zacks Equity Research

                                            Gilead's (GILD) HIV franchise is expected to maintain momentum and offset the decline from the HCV franchise.

                                              Zacks Equity Research

                                              Is a Beat in Store for Alexion (ALXN) This Earnings Season?

                                              by Zacks Equity Research

                                              Alexion is likely to provide details about the pipeline portfolio when it reports its second-quarter 2018 results on Jul 26.

                                                Sweta Killa headshot

                                                Healthcare ETFs to Buy on Solid Q2 Earnings Expectations

                                                by Sweta Killa

                                                With earnings surprises well in the cards, the healthcare sector is expected to witness earnings growth of 9.1% in the second quarter, suggesting continued outperformance for healthcare ETFs.

                                                  Zacks Equity Research

                                                  Amgen (AMGN) to Report Q2 Earnings: Will it Beat Again?

                                                  by Zacks Equity Research

                                                  While Amgen's (AMGN) growth drugs like Prolia & Xgeva might do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth.